Biologic facts
BrandRolvedon (Eflapegrastim)
No biosimilar to Rolvedon is licensed. The 12-year reference exclusivity date of 09/2034 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Rolvedon was first approved by the FDA in 2022; the application holder is Assertio Specialty Pharmaceuticals, LLC.
Holder Assertio Specialty Pharmaceuticals, LLCApproved 2022
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 09/203412-year estimate from first approval Purple Book
02Competition
- Biosimilars
- No biosimilar approved Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Rolvedon profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Assertio Specialty Pharmaceuticals, LLC Purple Book
- First approved
- 2022 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.